Drug Profile
Research programme: RNA-targeted therapeutics - Andes Biotechnologies
Alternative Names: Andes 1560Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Andes Biotechnologies
- Class Antisense oligoribonucleotides; Antisense RNA
- Mechanism of Action Apoptosis stimulants; RNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Chile (Parenteral)
- 16 Jun 2015 Research programme: RNA-targeted therapeutics - Andes Biotechnologies is available for licensing as of 16 Jun 2015. http://andesbiotechnologies.com/